Skip to main content
Log in

Aspetti endocrini dell’anoressia nervosa

  • Published:
L’Endocrinologo Aims and scope

Riassunto

L’anoressia nervosa è una patologia psichiatrica che ha avuto un notevole aumento di incidenza nel corso delle ultime decadi, caratterizzata dall’insorgenza tipicamente in età puberale. Prevalente nel sesso femminile e nelle società industrializzate, è gravata dalla più alta mortalità fra le malattie psichiatriche: a ciò contribuiscono le complicanze organiche del grave stato di denutrizione e l’elevata frequenza di suicidi. Sul versante endocrino, sono descritte anomalie più o meno rilevanti a carico di tutti gli assi funzionali. Tali alterazioni, reversibili con il recupero ponderale o la guarigione, costituiscono epifenomeni della malattia di base. L’ipogonadismo ipogonadotropo di origine ipotalamica dà luogo nei soggetti di sesso femminile all’amenorrea, che costituisce uno dei criteri diagnostici della malattia. La secrezione spontanea e stimolata delle gonadotropine riacquista caratteristiche tipiche della fase prepuberale, mentre appaiono ridotte le concentrazioni sieriche degli steroidi gonadici. L’asse ipotalamo-ipofisi-surrene risulta attivato, come in altre patologie psichiatriche (ad esempio, la depressione). Si segnalano elevati livelli liquorali di CRH, aumentata escrezione urinaria di cortisolo libero, abolizione del ritmo circadiano del cortisolo plasmatico e mancata soppressione della cortisolemia dopo test di inibizione rapida con desametasone a basse dosi. La low T 3 syndrome, comune ad altri stati di defedamento, deriva da una conversione preferenziale di T4 a reverse T3 piuttosto che a T3 nei tessuti periferici. Questo meccanismo, finalizzato al risparmio energetico, pur contribuendo alla bradicardia e all’intolleranza al freddo delle pazienti anoressiche, non necessita di terapia sostitutiva. Le anomalie dell’asse somatotropo configurano un quadro di resistenza all’azione del GH. A fronte infatti di un’esaltata secrezione somatotropinica, i livelli circolanti di IGF-I risultano francamente ridotti a causa della malnutrizione cronica. La secrezione spontanea del GH è amplificata per un aumento sia della componente pulsatile che di quella tonica, mentre la responsività dell’ormone ai vari stimoli farmacologici è estremamente variabile. A tali anomalie contribuiscono verosimilmente sia il mancato feedback negativo da parte dell’IGF-I sia alterazioni della secrezione ipotalamica di GHRH e somatostatina. Insieme alla carenza di sostanze nutritive e al basso peso corporeo, ipogonadismo, ipercortisolismo e deficit somatomedinico contribuiscono allo sviluppo di una osteopenia di entità tale da aumentare il rischio di fratture nel lungo termine. Tale osteoporosi sembra poco responsiva al trattamento con estroprogestinici, mentre risulterebbe più efficace la somministrazione di IGF-I biosintetico (terapia peraltro non proponibile al momento attuale data la scarsa reperibilità del farmaco, che viene interamente riservato al trattamento del nanismo di Laron) e di bisfosfonati.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Bibliografia

  1. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese women. N Engl J Med 334: 292, 1996.

    Article  CAS  PubMed  Google Scholar 

  2. Leal-Cerro A, Considine RV, Peino R, Venegas E, Astorga R, Casanueva FF, Dieguez C. Serum immunoreactive-leptin levels are increased in patients with Cushing’s syndrome. Horm Metab Res 28: 711, 1996.

    Article  CAS  PubMed  Google Scholar 

  3. Fisker S, Vahl N, Hansen TB, Jorgensen JOL, Hagen C, Orskov H, Christiansen JS. Serum leptin is increased in growth hormone-deficient adults: relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year. Metabolism 46: 812, 1997.

    Article  CAS  PubMed  Google Scholar 

  4. Casanueva FF, Dieguez C, Popovic V, Peino R, Considine RV, Caro JF. Serum immunoreactive leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. Biochem Mol Med 60: 116, 1997.

    Article  CAS  PubMed  Google Scholar 

  5. Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibanski A. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 89: 3486, 2004.

    Article  CAS  PubMed  Google Scholar 

  6. Holtkamp K, Hebebrand J, Mika C, Heer M, Heussen N, Herpertz-Dahlmann B. High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa. Psychoneuroendocrinology 29: 791, 2004.

    Article  CAS  PubMed  Google Scholar 

  7. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, Tschop M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145: R5, 2001.

    CAS  Google Scholar 

  8. Rigamonti AE, Pincelli AI, Corrà R, Viarengo R, Bonomo SM, Galimberti D, Scacchi M, Scarpini E, Cavagnini F, Muller EE. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 175: R1, 2002.

    Article  CAS  PubMed  Google Scholar 

  9. Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, De Giacomo P, Giorgino R, De Pergola G. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 88: 1748, 2003.

    Article  CAS  PubMed  Google Scholar 

  10. Iwahashi H, Funahashi T, Kurokawa N, Sayama K, Fukuda E, Okita K, Imagawa A, Yamagata K, Shimomura I, Miyagawa JI, Matsuzawa Y. Plasma adiponectin levels in women with anorexia nervosa. Horm Metab Res 35: 537, 2003.

    Article  CAS  PubMed  Google Scholar 

  11. Housova J, Anderlova K, Krizova J, Haluzikova D, Kremen J, Kumstyrova T, Papezova H, Haluzik M. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 90: 1366–1370, 2005.

    Article  CAS  PubMed  Google Scholar 

  12. Boyar RM, Hellman LD, Roffwarg H, Katz J, Zumoff B, O’Connor J, Bradlow HL, Fukushima DK. Cortisol secretion and metabolism in anorexia nervosa. N Engl J Med 296: 190, 1977.

    Article  CAS  PubMed  Google Scholar 

  13. Misra M, Miller KK, Almazan C, Ramaswamy K, Lapcharoensap W, Workey M, Neubauer G, Herzog DB, Klibanski A. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab 89: 4972, 2004.

    Article  CAS  PubMed  Google Scholar 

  14. Hotta M, Shibasaki T, Masuda A, Imaki T, Demura H, Ling N, Shizume K. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J Clin Endocrinol Metab 62: 319, 1986.

    Article  CAS  PubMed  Google Scholar 

  15. Cavagnini F, Invitti C, Passamonti M, Polli EE. Responses of ACTH and cortisol to corticotropin-releasing hormone in anorexia nervosa. N Engl J Med 314: 184, 1986.

    CAS  PubMed  Google Scholar 

  16. Kaye WH, Gwirtsman HE, George DT, Ebert MH, Jimerson DC, Tomai TP, Chrousos GP, Gold PW. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab 64: 203, 1987.

    Article  CAS  PubMed  Google Scholar 

  17. Scacchi M, Pincelli AI, Cavagnini F. Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa. Front Neuroendocrinol 24: 200, 2003.

    Article  CAS  PubMed  Google Scholar 

  18. Invitti C, Redaelli G, Baldi G, Cavagnini F. Glucocorticoid receptors in anorexia nervosa and Cushing’s disease. Biol Psychiatry 45: 1467, 1999.

    Article  CAS  PubMed  Google Scholar 

  19. Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch Gen Psychiatry 47: 548, 1990.

    Article  CAS  PubMed  Google Scholar 

  20. Boyar RM, Katz J, Finkelstein JW, Kapen S, Weiner H, Weitzman ED, Hellman L. Anorexia nervosa: immaturity of the 24-hour luteinizing hormone secretory pattern. N Engl J Med 291: 861, 1974.

    Article  CAS  PubMed  Google Scholar 

  21. Jeuniewic N, Brown GM, Garfinkel PE, Moldofsky H. Hypothalamic function as related to body weight and body fat in anorexia nervosa. Psychosom Med 40: 187, 1978.

    CAS  PubMed  Google Scholar 

  22. Frisch RE. Fatness and the onset and maintenance of menstrual cycles. Res Reprod 9: 1, 1977.

    CAS  PubMed  Google Scholar 

  23. Yu WH, Walczewska A, Karanth S, McCann SM. Nitric oxide mediates leptin-induced luteinizing hormone-releasing hormone (LHRH) and LHRH- and leptin-induced LH release from the pituitary gland. Endocrinology 138: 5055, 1997.

    Article  CAS  PubMed  Google Scholar 

  24. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O’Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 101: 4531, 2004.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351: 987, 2004.

    Article  CAS  PubMed  Google Scholar 

  26. Vulliemoz NR, Xiao E, Xia-Zhang L, Germond M, Rivier J, Ferin M. Decrease in luteinizing hormone pulse frequency during a five-hour peripheral ghrelin infusion in the ovariectomized rhesus monkey. J Clin Endocrinol Metab 89: 5718, 2004.

    Article  CAS  PubMed  Google Scholar 

  27. Popovic V, Djurovic M, Cetkovic D, Vojvodic D, Pekic S, Spremovic S, Petakov M, Damjanovic S, Milic N, Dieguez C, Casanueva FF. Inhibin B: a potential marker of gonadal activity in patients with anorexia nervosa during weight recovery. J Clin Endocrinol Metab 89: 1838, 2004.

    Article  CAS  PubMed  Google Scholar 

  28. Moshang T Jr, Parks JS, Baker L, Vaidya V, Utiger RD, Bongiovanni AM, Snyder PJ. Low serum triiodothyronine in patients with anorexia nervosa. J Clin Endocrinol Metab 40: 470, 1975.

    Article  PubMed  Google Scholar 

  29. Vigersky RA, Loriaux DL, Andersen AE, Mecklenburg RS, Vaitukaitis JL. Delayed pituitary hormone response to LRF and TRF in patients with anorexia nervosa and with secondary amenorrhea associated with simple weight loss. J Clin Endocrinol Metab 43: 893, 1976.

    Article  CAS  PubMed  Google Scholar 

  30. Stoving RK, Bennedbaek FN, Hegedus L, Hagen C. Evidence of diffuse atrophy of the thyroid gland in patients with anorexia nervosa. Int J Eat Disord 29: 230, 2001.

    Article  CAS  PubMed  Google Scholar 

  31. Scacchi M, Pincelli AI, Caumo A, Tomasi P, Delitala G, Baldi G, Cavagnini F. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. J Clin Endocrinol Metab 82: 3225, 1997.

    Article  CAS  PubMed  Google Scholar 

  32. Stoving RK, Veldhuis JD, Flyvbjerg A, Vinten J, Hangaard J, Koldkjaer OG, Kristiansen J, Hagen C. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: in direct evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J Clin Endocrinol Metab 84: 2056, 1999.

    CAS  PubMed  Google Scholar 

  33. Scacchi M, Invitti C, Pincelli AI, Pandolfi C, Dubini A, Cavagnini F. Lack of growth hormone response to acute administration of dexamethasone in anorexia nervosa. Eur J Endocrinol 132: 152, 1995.

    Article  CAS  PubMed  Google Scholar 

  34. Tamai H, Kiyohara K, Mukuta T, Kobayashi N, Komaki G, Nakagawa T, Kumagai LF, Aoki TT. Responses of growth hormone and cortisol to intravenous glucose loading test in patients with anorexia nervosa. Metabolism 40: 31, 1991.

    Article  CAS  PubMed  Google Scholar 

  35. Pincelli AI, Rigamonti AE, Scacchi M, Cella SG, Cappa M, Cavagnini F, Muller EE. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity. Eur J Endocrinol 148: 237, 2003.

    Article  CAS  PubMed  Google Scholar 

  36. Broglio F, Gianotti L, Destefanis S, Fassino S, Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland L, Van der Lely AJ, Ghigo E. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol 60: 592, 2004.

    Article  CAS  Google Scholar 

  37. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulinlike growth factors. Endocr Rev 15: 80, 1994.

    CAS  PubMed  Google Scholar 

  38. Masuda A, Shibasaki T, Hotta M, Suematsu H, Shizume K. Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion. J Endocrinol Invest 11: 297, 1988.

    CAS  PubMed  Google Scholar 

  39. Gianotti L, Pincelli AI, Scacchi M, Rolla M, Bellitti D, Arvat E, Lanfranco F, Torsello A, Ghigo E, Cavagnini F, Muller EE. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa. J Clin Endocrinol Metab 85: 2805, 2000.

    CAS  PubMed  Google Scholar 

  40. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 238: 298, 1982.

    Article  CAS  PubMed  Google Scholar 

  41. Tolle V, Kadem M, Bluet-Pajot MT, Frere D, Foulon C, Bossu C, Dardennes R, Mounier C, Zizzari P, Lang F, Epelbaum J, Estour B. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 88: 109, 2003.

    Article  CAS  PubMed  Google Scholar 

  42. Wentz E, Mellstrom D, Gillberg C, Sundh V, Gillberg IC, Rastam M. Bone density 11 years after anorexia nervosa onset in a controlled study of 39 cases. Int J Eat Disord 34: 314, 2003.

    Article  PubMed  Google Scholar 

  43. Munoz MT, Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. Eur J Endocrinol 147: 275, 2002.

    Article  CAS  PubMed  Google Scholar 

  44. Milos G, Spindler A, Ruegsegger P, Seifert B, Muhlebach S, Uebelhart D, Hauselmann HJ. Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos Int 16: 783, 2005.

    Article  PubMed  Google Scholar 

  45. Weinbrenner T, Zittermann A, Gouni-Berthold I, Stehle P, Berthold HK. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa: a case-control study. Eur J Clin Nutr 57: 1262, 2003.

    Article  CAS  PubMed  Google Scholar 

  46. Kahl KG, Rudolf S, Dibbelt L, Stoeckelhuber BM, Gehl HB, Hohagen F, Schweiger U. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporos Int 16: 424, 2005.

    Article  CAS  PubMed  Google Scholar 

  47. Misra M, Soyka LA, Miller KK, Herzog DB, Grinspoon S, De Chen D, Neubauer G, Klibanski A. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88: 3816, 2003.

    Article  CAS  PubMed  Google Scholar 

  48. Coen G. Leptin and bone metabolism. J Nephrol 17: 187, 2004.

    PubMed  Google Scholar 

  49. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 87: 4935, 2002.

    Article  CAS  PubMed  Google Scholar 

  50. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87: 2883, 2002.

    Article  CAS  PubMed  Google Scholar 

  51. Miller K, Grieco K, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 90: 1428, 2005.

    Article  CAS  PubMed  Google Scholar 

  52. Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Herzog DB, Klibanski A. Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 89: 3903, 2004.

    Article  CAS  PubMed  Google Scholar 

  53. Mecklenburg RS, Loriaux DL, Thompson RH, Andersen AE, Lipsett MB. Hypothalamic dysfunction in patients with anorexia nervosa. Medicine 53: 147, 1974.

    Article  CAS  PubMed  Google Scholar 

  54. Frank GK, Kaye WH, Altemus M, Greeno CG. CSF oxytocin and vasopressin levels after recovery from bulimia nervosa and anorexia nervosa, bulimic subtype. Biol Psychiatry 48: 315, 2000.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesco Cavagnini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scacchi, M., Fedeli, C., Ascoli, P. et al. Aspetti endocrini dell’anoressia nervosa. L’Endocrinologo 6, 155–167 (2005). https://doi.org/10.1007/BF03344526

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344526

Navigation